Effect of increase bowel motility with senokot on the predialysis serum potassium in maintenance hemodialysis patient

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210303001

Enrollment

Registered

2021-03-03

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance hemodialysis patients with predialysis plasma potassium 5.1-6.0 mEq/L and adequate dialysis Hyperkalemia Hemodialysis Senna glycoside Bowel motility

Interventions

None,Senokot supplementation

No Intervention No treatment,Experimental Drug

Control group,Senokot group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 18 years Trice weekly MHD at least 3 months with spKT/V > 1.2 Serum potassium 5.1-6.0 mEq/L Informed consent

Exclusion criteria

Exclusion criteria: Hospitalization within 3 months Significant intraabdominal or GI obstruction, infection, malignancy Secondary cause of constipation or severe constipation

Design outcomes

Primary

Measure	Time frame
pre dialysis serum potassium (mid-week) 8 weeks mEq/L	—

Secondary

Measure	Time frame
serum potassium 8 weeks mEq/L	—

Countries

Thailand

Contacts

Public ContactWasin Bunpeth

Department of Internal Medicine, Phramongkutklao Hospital

wasin_net@hotmail.com0849313240

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026